Detail akcie PDS Biotech Rg-B online

Business Summary: PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, PDS Biotechnology Corp revenues was not reported. Net loss decreased 9% to $26.9M. Lower net loss reflects Research and Development Expenses - Bala decrease of 14% to $13.9M (expense), General and administrative decrease of 34% to $2.3M (expense), Research and development decrease of 61% to $682K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.61.